BCL7B

Across TCGA pan-cancer cohorts, BCL7B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BCL7B data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher BCL7B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BCL7B expression acts as an unfavorable survival marker.

OV and COAD are the cancer types where BCL7B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.180	0.846	<.001	36	view →
COAD	OS	Median	All	0.001	0.871	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

BCL7B–OV (OS)

Open the OV breakdown →